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Abstract 
Abstract of thesis entitled 
Virological Characteristics of Hepatitis B e Antigen-Negative Chronic Hepatitis 
B Virus Infection in China 
Submitted by ZHU Lin 
For the degree of Master of Philosophy in medical science 
at The Chinese University of Hong Kong in June 2007 
Spontaneous hepatitis B e antigen (HBeAg) seroconversion is initially 
regarded as successful immune clearance of hepatitis B virus (HBV). However, 
HBeAg-negative chronic hepatitis B has been well reported to associate with liver 
cirrhosis and hepatocellular carcinoma (HCC) and it therefore presents a health threat 
no less than HBeAg-positive chronic hepatitis. 
My study aimed to investigate the distribution of hepatitis B vims (HBV) 
genotypes/subgenotypes in different parts of China and their clinical impact on the 
severity of HBeAg-negative chronic hepatitis B. Residual serum samples from a 
cohort of HBeAg-negative chronic hepatitis B patients in Hong Kong, Shanghai and 
Beijing were studied. Complete HBV genomic sequencing was performed for 
phylogenetic analysis and determination of HBV mutations. Mutations associated 
with severe liver fibrosis (Ishak score 4 or more) were selected by computerized 
information gain criteria. 
Genotype B (all subgenotype Ba) HBV was present in 19 of 45 (42%), 12 of 
31 (39%) and 5 of 25 (20%) patients in Hong Kong, Shanghai and Beijing, 
respectively (p=0.16). Ninety-seven percent of genotype C HBV in Shanghai and 
Beijing belonged to subgenotype Ce whereas 69% of genotype C HBV in Hong 
Kong belonged to subgenotype Cs (p<0.001). Patients infected by HBV subgenotype 
Cs had lowest serum albumin and highest ALT as compared to HBV subgenotype Ce 
and Ba. Patients infected by HBV subgenotype Cs also had more severe histologic 
necroinflammation than HBV subgenotype Ce. Two HBV mutations were identified 
to associate with severe liver fibrosis (G2858C and C2289A) and one mutation was 
protective against severe liver fibrosis (T2201C). T2201 mutation was found 
exclusively among patients (21 of 46 patients, 45%) infected by HBV subgenotype 
Ce. 
In conclusion, the clinical differences of HBeAg-negative chronic hepatitis B 












基因亞型Ce，而69%的位於香港的基因型C病人屬於基因亞型Cs (P<0. 001 ) . 
當比較與其他兩個基因亞型時，基因亞型Cs病人攜帶有最少量的血清白蛋白 
以及顯著增高的穀丙轉氨酶含量；且基因亞型Cs病人有著比Ce病人更加嚴重 
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1.1 Viral Hepatitis 
Hepatitis is the inflammation of the liver. An important cause of 
hepatitis is infection by specific hepatitis viruses that primarily attack the 
liver. The commonest hepatitis virus infections in Asia are hepatitis A 
virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV) and 
hepatitis E virus (HEV). Infection of these viruses may lead to acute form 
of hepatitis in which most patients experience a complete recovery. HAV 
and HEV can only cause acute hepatitis but will never develop into 
chronicity. On the other hand, infection by HBV and HCV can develop 
into chronic hepatitis (Blumberg, 1997). In the case of chronic hepatitis, 
the vims can exist and replicate in the liver for years or decades, which 
leads to destruction of the liver cells and damage of the liver function. 
Patients with chronic hepatitis may develop life-shortening complications 
such as hepatocellular carcinoma (HCC) (Ganem D. et al., 1987). 
Complications may develop without precedent clinical symptomatic acute 
hepatitis. During the chronic hepatitis infection, many patients do not 
develop any symptom of disease and remain as asymptomatic carriers for 
years or even decades. 
2 
1.2 Global Epidemiology of HBV 
HBV infection is one of the major health problems worldwide. 
According to the most recent estimation by World Health Organization, 
two billion people have been infected by this virus and 360 million people 
are chronic carriers of HBV worldwide (World Health Organization 2004, 
Shepard C.W. et al., 2006). There are about 0.5-0.7 million deaths 
annually over the world due to severe HBV-related liver diseases such as 
liver cirrhosis and HCC (Wands & Blum, 1991, World Health 
Organization 2000, World Health Organization 2004). Chronic HBV 
infection has become one of the leading causes of death in the world and it 
attributes up to 80% of the primary HCC cases, which is currently the fifth 
most frequent cancer and third most common cause of cancer-related death 
worldwide (Lavanchy D, 2004). 
The prevalence of HBV infection and pattern of transmission 
varies geographically (Mahoney F.J., 1999, Shepard C.W. et al.，2006). 
Generally, the prevalence of HBV infection is increasing with age and the 
carrier rates is related to the dominant mode of transmission as well as age 
of infection in different geographical areas. The age that infection takes 
place has an important impact on the clinical outcome. Chronic HBV 
infection develops in approximately 90% of infants infected at birth, 
around 25-50% of children infected between the age of 1 to 5 years and 
only less than 5% of people infected in young adulthood (Stevens et al., 
1975; Beasley et al., 1982; Tassopoulos et al., 1987). 
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1.3 Modes of transmission 
Transmission of HBV can occur via multiple routes, such as 
perinatal transmission from an infected mother to her infant, horizontal 
transmission by percutaneous or permucosal exposure to infectious body 
fluids and by sexual contact with an infected person (Mahoney F.J., 1999). 
The highest concentrations of infectious HBV are found in blood. 
However, other serum-derived body fluids, such as semen and saliva, are 
also infectious (Bond W.W., et al., 1977). As HBV can remain stable and 
infectious on environmental surfaces for more than seven days, infection 
may occur indirectly via contaminated surfaces and other objects. The 
route of transmission affects the clinical outcome as the probability of 
developing chronic hepatitis B of perinatal transmission or preschool 
infection is very high (Chen et al., 2000). 
In highly endemic area such as Hong Kong and mainland China, 
perinatal transmission is the major cause accounting for 40-50% of 
chronic HBV infection (Steven et al., 1975; Lok et al., 1987a). As for 
other areas of high endemicity such as Middle East and Africa, the lifetime 
risk of HBV infection is >60% and most infections occur during the first 
two years of life (Kew 1996; Toukan 1996). In area with an intermediate 
prevalence, early childhood infection by perinatal or horizontal 
transmission accounts for most of the cases of chronic infection. In 
countries with a low prevalence, most HBV infections are transmitted by 
sexual intercourse or needle sharing by intravenous drug users. 
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1.4 Diagnostic tests 
The diagnosis of HBV infection was revolutionized by Blumberg 
in 1965 due to discovery of HBsAg (Blumberg et al., 1965). Serological 
assays for HBsAg and hepatitis B surface antibody (anti-HBs) with 
inproved sensitivity and specificity were developed afterwards. In 1970s, 
serological assays for new-discovered HBV antigens and antibodies were 
established. The biological significances of these serological assays are 
shown in Table 1.4.1. 
Since 1980s, improvement in molecular biology led to 
development of various assays for HBV DNA detection including 
hybridization assays with special oligonucleotides that directly determinate 
of viral replication and polymerase chain reaction (PGR) assays that 
permit the detection of tiny amount of HBV DNA in the serum. 
5 
Table 1.4.1 
Interpretation of HBV Serological Markers 
HBsAg HBV infection: acute or chronic 
HBeAg Replication phase: high level of replication and infectivity 
Anti-HBe Low replication phase: low level of replication and 
infectivity 
Anti-HBc Recent HBV infection 
IgM Or exacerbation of chronic HBV infection 
Anti-HBc Recovered HBV infection 
IgG Or chronic HBV infection 
Anti-HBs Immunity of HBV infection via: 
Recovered HBV infection 
Or vaccinated 
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1.4.1 HBeAg and Anti-HBe 
HBeAg is a secretory processed product of precore protein and it is 
generally considered as a marker of HBV replication and infectivity. The 
presence of HBeAg in serum is often associated with detection of HBV 
DNA (Fong et al., 1994) and HBV polymerase (Alter et al , 1976). The 
perinatal transmission rate in HBeAg-positive carrier mothers to their 
babies is significantly higher than that of the HBeAg-negative carrier 
mothers (Okada et al., 1976; Hwang et al., 1985). 
In patients with chronic HBV infection, HBeAg may persist for 
years or even decades. For patients who acquired HBV infection 
perinatally, there may be an immune tolerance phase with high HBV DNA, 
normal alanine aminotransferase levels and minimal inflammation in liver 
(Lok and Lai 1988; Chang et al., 1988). Seroconversion from HBeAg to 
anti-HBe is usually associated with decreasing levels of HBV DNA and 
remission of liver disease (Fattovich et al., 1986; Realdi et al., 1980). 
However, a small proportion of patients with positive anti-HBe continue to 
have active liver disease and detectable HBV DNA in serum (Lieberman 
et al., 1983; Lok et al, 1984). 
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1.4.2 Serum enzymes 
During inflammation of the hepatocytes, enzymes are released 
from necrotic tissues to the blood. Transaminases, including alanine 
transaminase (ALT) and aspartate transaminase (AST) are the two most 
sensitive indicators reflecting the degree of necro-inflammation in acute 
hepatitis. In acute HBV infection (except the perinatal transmission), 
transaminase levels are usually elevated and precede the onset of jaundice. 
In chronic HBV infection, the use of transaminases in diagnosis is 
less certain. Biochemical exacerbations with more than 2 to 3 fold 
elevation of transaminase levels often occur during immune clearance of 
the vims (Liaw et al., 1983; Lok et al., 1987; Bortolotti et al., 1990). In the 
immune tolerance phase, the transaminase levels are either normal or 
mildly elevated. The clinical significance of mild elevation of 
transaminases is not clear. It is reported that elevation of transaminases 
among anti-HBe-positive chronic HBV infected patients is associated with 
histological chronic active hepatitis (ter Borg et al., 1998). However, as the 
disease course of anti-HBe-positive chronic HBV infected patients tends to 
fluctuate with time and so as the histologic necro-inflammatory activity, 
the use of transaminase for prediction of disease activity in these patients 
remains to be determined. 
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1.4.3 HBV DNA Assays 
1.4.3.1 HBVDNA Assays 
There are several HBV DNA assays developed in the past decade 
with different sensitivity. The most widely used non-PCR based assay in 
therapeutic trials of anti-viral therapy for chronic HBV infection is the 
VERSANT HBV DNA 1.0 Assay (VERSANT 1.0); which was initially 
referred as bDNA assay. The assay increases its sensitivity by using signal 
amplification of the synthetic bDNA molecules. The lower limit of 
detection is approximately 700,000 copies of HBV per milliliter. Another 
method of HBV DNA assay is RNA-DNA hybrid assay developed by 
Digene Diagnostic Corporation (USA). Although the first generation assay 
is proved to be less sensitive than bDNA assay (Butterwoth et al., 1996), 
the second generation of assay is refined with amplified signal. The lower 
detect limit of the assay can reach as low as 140,000 copies per mL. 
Recently, a third-generation branched-DNA (bDNA) assay for the direct 
quantification of HBV DNA in human serum and plasma was developed 
and named as VERSANT HBV DNA 3.0 Assay. This test has shown 
excellent reproducibility, and a broad linear range of quantification (2.0 x 
10^  to 1.0 X 10^  HBV DNA copies/mL) that facilitates the monitoring of 
HBV DNA levels at diagnosis and throughout the course of treatment 
(Yao et al., 2004). 
There are several PCR-based HBV DNA assays as well. The Cobas 
Amplicor Monitor Test, a more sensitive assay developed by Roche 
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(Switzerland), increases the sensitivity of assay to 200 viral copies per mL 
(Noborg et al., 1999). Another quantitative PGR assay using real-time 
fluorescent-probe PGR, the TaqMan PCR system, has been described 
recently. It has been shown to be much sensitive than the Versant assay 
and the results are highly reproducible (Leob et al., 2000). PCR based 
assays are found to be much more sensitive than non-PCR based assays 
such as bDNA assay, and the results are highly reproducible (Loeb et al., 
2000). 
1.4.3.2 Clinical Applications ofDNA Assays 
The major function of serum HBV DNA assays in patients with 
chronic HBV infection is to assess HBV replication and candidacy for 
antiviral therapy. Patients with high pre-treatment serum HBV DNA level 
are less likely to respond to interferon therapy (Perrilllo et al., 1990). The 
value of 100,000 viral copies/mL has been suggested as a cutoff for the 
threshold of HBV replication (Lok and McMahon, 2003) and serum HBV 
DNA over 10,000 viral copies/mL is associated with progression of CHB 
to outcomes such as HCC (Zacharakis et al., 2005; Tang et al., 2004). 
Therefore it is reasonable to consider serum HBV DNA as an indicator for 
both viral replication and treatment goal (Farrell and Teoh, 2006). 
Tests for HBV DNA in serum are also important for assessing 
response to antiviral treatment. Currently, viral response is preferably 
evaluated by PCR-based HBV DNA assays. It is arbitrarily considered to 
be achieved when serum HBV DNA falls below 100,000 copies/mL (Lok 
10 
et al., 2001; Lok and McMahon, 2001). However, more effective HBV 
suppression is probably necessary with serum HBV DNA levels fall below 
400 or even 200 copies/mL, the cutoff levels of the Roche Monitor assay 
or of most in-house real-time PCR assays (Gerken et al., 1998; Pawlotsky 
2002). 
HBV DNA tests are essential for assessment of HBeAg-negative 
CHB patients as well. A serum HBV DNA level of 100,000 copies/mL is 
the essential distinction between HBeAg seroconversion and mutation of 
HBV to HBeAg-negative variants (Farrell and Teoh, 2006). Unlike 
HBeAg-positive patients, clearance of HBsAg among these patients, 
which may eventually develop in only about 20 to 25% of sustained 
responders (Brunetto et al., 1995; Manesis and Hadziyannis, 2001), occurs 
rather infrequently and late. Therefore the goals of therapy in HBeAg-
negative CHB are restricted to virological and biochemical responses 
(Papatheodoridis and Hadziyannis, 2001; Lok and McMahon, 2001). A 
study showed that a sustained biochemical response accompanied by low 
residual HBV DNA levels, is associated with a reduced risk of 
development of liver decomposition and/or HCC and with improved 
survival (Papatheodoridis et al., 2001). Thus HBV DNA is important for 
monitoring the disease activity of HBeAg-negative CHB patients and 
could be used as a treatment goal of these patients (Papatheodoridis and 
Hadziyannis, 2001). 
11 
Rarely, HBV DNA assays help to identify HBV as etiology of liver 
disease in HBsAg-negative patients (Brechot et al., 1985). For patients 
with fulminant hepatitis B who have cleared HBsAg by that time, the 
assay is particular important (Wright et al., 1992). 
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1.4.4 Histology 
Liver biopsy is useful in assessing the severity of liver damage, 
predicting prognosis and monitoring response to treatment. Inflammatory 
cell infiltration in portal tracts and periportal necrosis are the major 
histological findings of chronic HBV infection. As the liver disease 
progresses, fibrous tissue is deposited firstly within the portal tracts, then 
extended into the centrilobular areas and adjacent portal tracts forming 
bridging fibrosis and eventually cirrhosis. In some patients, ground glass 
hepatocytes are seen, indicating retention of HBsAg (Chisari 1989; 
Schirmacher et al., 1995). 
To provide objective assessment of liver injury, several scoring 
systems have been established to compare the necro-inflammation activity 
and fibrosis (Hytiroglou et al., 1995). The most popular system is 
proposed by Knodell, which grades the severity of periportal and bridging 
necrosis, intralobular degeneration and focal necrosis, portal inflammation 
as well as fibrosis (Knodell et al, 1981). A histological activity index 
(HAI) is derived by adding the individual scores of the four components 
giving a score ranging from 0-22 (Table 1.4.1). The necro-inflammation 
score (0-18) is the sum of the scores for periportal and bridging necrosis, 
intralobular degeneration, focal necrosis as well as portal inflammation; 
while the fibrosis score ranges from 0 to 4. One problem for Knodell 
system is the discontinuous scale. As a result, a modified HAI grading has 
been proposed by Ishak (Ishak et al, 1995); in which the necro-
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inflammation and fibrosis are separately assessed, a continuous scale is 
used and the fibrosis score changed to range 0-6 (Table 1.4.2, 1.4.3). 
There are still several problems for all the histological scoring 
systems. The histological scores are not representing the measurement of 
continuous variable but different categories of severity. As it is not true 
numerical progression, non-parametric test should be used for statistical 
analysis. Secondly, the inter-observer variation can not be avoided. 
Thirdly, sampling variation may exist on needle biopsy at different parts of 
liver, in term of both necro-inflammation and fibrosis. 
Adequate representative liver biopsy is necessary. The current 
recommendation for chronic viral hepatitis is that the biopsy should be at 
least 20 mm length (1.4 mm diameter) and should contain at least 11 
complete portal tracts. Smaller biopsies are likely to be unrepresentative 
and they will tend to underestimate both disease grade and stage. 
Variability increases with smaller samples. Recognition of the limitations 
of interpretation of small biopsies is essential in the management of 
patients and in the therapeutic trial setting (Standish et al., 2006). 
14 
Table 1.4.1 
Histological Activity Index (Knodell score) 
Periportal and bridging necrosis 
Score Description 
0 None 
1 Mild piecemeal necrosis 
3 Moderate piecemeal necrosis (<50% of circumferential of most 
tracts) 
4 Marked piecemeal necrosis (>50% of circumferential of most 
tracts) 
5 Moderate piecemeal necrosis and bridging necrosis 
6 Marked piecemeal necrosis and bridging necrosis 
10 Multilobular necrosis 
Intralobular degeneration and focal necrosis 
Score Description 
0 None 
1 Mild (acidophilic bodies, ballooning degeneration and /or 
scattered foci of necrosis in <1/3 of lobules or nodules) 
3 Moderate (involvement of 1/3-2/3 lobules or nodules) 




1 Mild (few inflammatory cells in <1/3 of tracts) 
3 Moderate (increased inflammatory cells in 1/3-2/3 of tracts) 
4 Marked (numerous inflammatory cells in >2/3 of tracts) 
Fibrosis 
Score Description 
0 No fibrosis 
1 Fibrous portal expansion 




Modified HAI: Necro-inflammatory score (Ishak score) 
Change Score 
A. Periportal or periseptal interface hepatitis (piecemeal necrosis) 
Absent 0 
Mild (focal, few portal areas) 1 
Mild/moderate (focal, most portal areas) 2 
Moderate (continuous around <50% of tracts of septa) 3 
Severe (continuous around >50% of tracts of septa) 4 
B. Confluent necrosis 
Absent 0 
Focal confluent necrosis 1 
Zone 3 necrosis in some areas 2 
Zone 3 necrosis in most areas 3 
Zone 3 necrosis and occasional portal-central bridging 4 
Zone 3 necrosis and multiple portal-central bridging 5 
Panacinar or multiacinar necrosis 6 
C. Focal (spotty) lytic necrosis, apoptosis and focal inflammation 
Absent 0 
One focus or less per lOx objective 1 
Two to four foci per lOx objective 2 
Five to ten foci per lOx objective 3 
More than ten foci per 1 Ox objective 4 
D. Portal inflammation 
None 0 
Mild, some or all portal areas 1 
Moderate, some or all portal areas 2 
Moderate/marked, all portal areas 3 
Marked, all portal areas 4 
Maximum possible score 18 
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Table 1.4.1 
Modified HAI: Fibrosis score (Ishak score) 
Change Score 
No fibrosis 0 
Fibrous expansion of some portal areas, with or without short 1 
fibrosis septa 
2 
Fibrous expansion of most portal areas, with or without short 
fibrosis septa 3 
Fibrous expansion of most portal areas with occasional portal to 
portal bridging 4 
Fibrous expansion of most portal areas with marked bridging 
(portal-portal or portal-central) 5 
Marked bridging with occasional nodules (incomplete cirrhosis) 6 
Cirrhosis, probable or definite 
Maximum possible score 6 
17 
1.5 Natural course of chronic HBV infection 
The natural course of HBV infection is determined by two factors: 
viral replication and the host immune response. 
1.5.1 Phases of chronic hepatitis B 
The natural history of chronic HBV infection can be divided into 
several phases (Figure 1.5.1). The first stage of chronic carrier is a high 
viral replication phase with high level of HBV DNA. The HBsAg and 
HBeAg are both positive in this stage. For adult-infected patients, the 
replication phase is accompanied with elevated ALT levels and significant 
liver damage may exist on liver biopsy (Gust, 1996; Lok et al., 1987a). For 
patients who are infected by HBV perinatally, there is an initial phase in 
which viral replication is accompanied with normal ALT levels and 
minimal damage on histology (Lok and Lai 1988; Hsu et al., 1987). The 
lack of liver disease despite high level of viral replication during this phase 
is believed to be due to immune tolerance to HBV. The immune tolerance 
phase can last for a few years to decades. 
The second phase is the immune clearance phase when HBV is 
cleared with seroconversion from HBeAg to anti-HBe. Seroconversion is 
frequently accompanied by biochemical exacerbations, which can mimic a 
de novo attack of acute hepatitis B with the exceptional existence of anti-
HBe (Liaw et al, 1983; Lok et al 1987; Liaw et al., 1987). The annual rate 
18 
of spontaneous clearance of HBeAg is about 10-20% (Alward et al., 1985; 
Liaw et al., 1983). For patients who acquired the infection by perinatal 
infection, the cumulative rate of HBeAg clearance is approximately 2% 
during first 3 years (Chang et al., 1995) and 15% after 20 years of 
infection (Lok et al., 1987b). Coincident with seroconversion of HBeAg, 
HBV DNA level drops and ALT level falls to normal. Low viral 
replication predicts diminished infectivity and mild liver damage. 
The third phase is the low replication phase when patients are 
HBeAg-negative and anti-HBe-positive. Viral replication is usually low 
and liver inflammation is in remission. With time, some of these patients 
may become HBsAg-negative and enter the no viral replication phase. The 
annual rate of HBsAg seroconversion among chronic HBV infection has 
been estimated to be 0.5%-2% (Hsu et al., 1992b; Alwards et al., 1985; 
Liaw et al., 1991; Villeneuve et al., 1994). Many patients have low viral 
replication and inactive liver disease after seroconversion of HBeAg. 
Reactivation of HBV replication with reappearance of HBeAg and HBV 
DNA may occur when these patients are immunosuppressed (Lok et al., 
1991) or induced by chemotherapy (Flowers et al., 1990). Reactivation can 
be mild or severe and cause fulminant hepatic failure (Lau et al., 1989; 
Davis et al., 1984), and it could happen after HBsAg seroconversion in 
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1.5.2 HBeAg-negative chronic hepatitis B 
Spontaneous hepatitis B e antigen seroconversion is initially 
regarded as successful immune clearance of hepatitis B virus (Hoofnagle 
et al, 1981). However, a number of HBeAg-negative patients continue to 
have moderate HBV replication, elevated ALT levels and active liver 
diseases on biopsy (Fattoivich et al., 1986; Lok et al., 1984). Up to one 
third of HBeAg-negative patients have viral relapse of hepatitis after a 
seroconversion of HBeAg (Lok et al., 1987b; Fattoivich et al., 1986). 
HBeAg-negative chronic hepatitis B has been well reported to associate 
with liver cirrhosis and HCC (Brunette et al, 1991; Hadziyannis et al., 
1983; Bonino et al., 1986). Patients suffering from HBeAg-negative active 
liver disease often indicate an abortive effort of immune clearance of the 
virus (Carman et al., 1995). Such patients are initially described in the 
Mediterranean countries but are also prevalent in Asia (Fattoivich et al., 
1986; Akahane et al., 1990; Lok et al., 1994). The prevalence of HBeAg-
negative CHB among HBsAg-positive patients was 33% in the 
Mediterranean, 15% in Asia Pacific, and 14% in the United States and 
Northern Europe (Funk et al, 2002). It was reported that abut 32% of 
HBsAg-positive/HBeAg-negative patients belong to HBeAg-negative 
CHB (Funk et al., 2002); and HBeAg-negative patients account for 60% 
to 90% of all chronic hepatitis B patients in most Southeast Asian 
countries (Gust, 1996). The HBeAg-negative CHB therefore presents a 
health threat no less than HBeAg-positive CHB. 
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A number of HBV mutations have been found to be associated 
with HBeAg-negative, persistent infections. It is reported that precore stop 
codon mutation (G to A at nucleotide 1896, G1896A) and basal core 
promoter mutations (mutations A to T at nucleotide 1762 and G to A 
nucleotide 1764; A1762T and G1764A) increase the replication capacity 
of HBV by ceasing production of HBeAg without affecting expression of 
HBcAg and production of infectious virions (Buckwood et al., 1996; 
Gunther et al., 1998; Elizabeth and Tim 2000). These mutations could be 
selected during the process of HBeAg seroconversion by host immune 
response or treatment. 
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1.6 Molecular biology of HBV 
1.6.1 Overview 
HBV belongs to the hepadnavirus, a family of enveloped, 
hepatotrophic viruses with small partial double-stranded DNA genome 
(Murphy, 1995). The virion of HBV was firstly visualized under electron 
microscopy as “Dane particle" by Dane in 1970 (Dane et al” 1970) (Figure 
1.6.1). This particle has a 42-mn spherical structure that consists of an 
outer envelope and inner core. The outer envelope is about 8 nm in width 
and contains membrane lipids as well as a mosaic comprising 25 
kilodalton (kDa) glycoprotein antigens (the HBsAg). Enclosed by the 
outer envelope is a 27-nm nucleocapsid that carries the hepatitis B core 
antigen (HBcAg). Inside the HBcAg, the nucleocapsid contains the viral 
genomic DNA (Robinson et al., 1974) together with a 5'-covalently bound 
protein (Gerlich and Robinson, 1980) and an endogenous DNA 
polymerase (Kaplan et al., 1973). The HBeAg is found to be secreted from 
infected hepatocyte. There are two additional structures found in the serum 
of infected patients, 22-nm spherical aggregates and tubular filaments of 
22 nm diameter and up to 1000 nm long (Bayer et al., 1968). Both 
structures are consisted of HBsAg and do not contain viral DNA 
(Gavianes et al., 1982). Those structures are found non-infectious but still 
immunogenic (Bayer et al” 1968). 
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1.6.2 Genomic structure and organization 
The genome of HBV is a partially double-stranded, covalently 
closed circular DNA molecule. The minus strand is approximately 3200 
nucleotides long with completed genomic sequence, except a nick near the 
5' end of positive strand and is therefore not a closed circle. The positive 
strand is incomplete and lacks 15�50% from its nucleotide complement at 
its 3' end (Summers et al, 1975). The enclosed circular structure is 
maintained by a 226 base pair cohesive overlap between the 5 ‘ ends of the 
two strands (Sattler and Robinson 1979). There are two direct repeat 
sequences (DR) of 11 -base pair (bp) long at the 5 ‘ end of both strand of 
DNA named as DRl and DR2, which are required for viral replication 
(Seeger et al., 1986; Will et al., 1987). The minus strand encodes all the 
viral proteins and consists of four partially overlapping open reading 
frames (ORFs): surface, precore/core, polymerase and X (Figure 1.6.2). 
1.6.2.1 Surface ORF 
There are three in-frame start codons inside the ORF of surface 
gene and therefore split the gene into three regions: pre-Sl, pre-S2 and S 
regions (Galibert etal., 1979). Translation starts from three different start 
codons and ends at the same C-terminal, resulting three different gene 
product named the small (S), the middle (M) and the large (L) proteins. 
The molecular weight of these products is 25, 31 and 43 kDa respectively 
(Tiollais et al., 1985) (Figure 1.6.3). The M and S envelope proteins are 
normally seen as viral and subviral particles, while the L protein exists 
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predominant in the complete virions. There is a hepatocyte binding site 
within the pre-S 1 region which is essential for the viral entry into the host 
cell. The ‘a，determinant located in the S gene product is highly antigenic 
and composed by amino acids 120 to 147. 
1.6.2.2 Precore/core ORF 
The precore/core region contains two in-phase start codons, the 
precore and core start codons (Figure 1.6.4). The 3.5 kb pregenomic RNA 
starts from the core start codon and serves as the template for reverse 
transcription of the minus strand HBV DNA as well as the mRNA encodes 
for 22 kDa core protein (HBcAg) and the polymerase protein. The precore 
mRNA is initiated 87 nucleotides upstream the pregenomic RNA starting 
from the precore start codon. It is heterogeneous and comprised of short 
and long mRNAs with starting sites separated by 10 nucleotides. The 
precore mRNA encodes for a precursor protein that contains the entire 
precore/core gene. The product is processed at both ends and resulted in an 
18.5 kDa secretory protein: HBeAg (OU et al., 1986). HBeAg is 
commonly concentrated in the serum, however, there is also some 
incorporated into the outer cell membrane (Schlicht and Schaller 1989). 
Both HBeAg and HBcAg are targets for immune viral clearance 
mechanisms. 
J.6.2.3 Polymerase ORF 
The polymerase ORF is the longest ORF covering about 80% of 
the genome and overlaps with all other three ORFs. The ORF is divided 
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into three domains: the terminal protein domain, the reverse transcriptase 
domain and the RNase H domain. The terminal domain is responsible for 
protein priming of reverse transcription (Wang and Seeger 1992) and 
initiation of the negative strand synthesis (Weber et al., 1994). The reverse 
transcriptase synthesizes the genomic DNA and RNase H domain degrades 
the RNA template. A nonessential-functional spacer sequence separates 
the terminal domain and the polymerase domain in this ORF. 
1.6.2.4XORF 
The X ORF encodes the HBX protein, which is involved in 
transactivation of a variety of cellular and viral gene expression. The HBX 
protein is thought to be involved in the carcinogenesis process of HBV as 
well. It is reported that HBX could transform non-tumorigenic cell lines 
(Koike et al., 1989; Hohne et al., 1990) and high level of HBX expression 
is associated with liver tumor development on transgenic mice (Kim et al., 
1991; Koike et al., 1994). 
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Figure 1.6.1 
Electronic microscopy of HBV 
_ 
From public health image library, ID#: 5631. This image is in the public 
domain and thus free of any copyright restrictions. 
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Figure 1.6.1 
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1.7 Genetic variation of HBV 
Although HBV is a DNA virus, its mutation rate is much higher 
than other DNA virus. The significant propensity for mutation is due to the 
involvement of an RNA intermediate during its replication process. The 
covalent closed circular DNA (cccDNA) of HBV in the infected 
hepatocytes is used as the template for transcription of all viral RNAs by 
cellular RNA polymerase. The pregenomic RNA synthesized is then 
reverse transcribed by viral polymerase to produce the genomic HBV 
DNA. Both polymerases are lack of proofreading mechanism and the 
phenomenon increases the rate of mutation. A consequence of the unique 
replication system is a huge genetic variation pool for selection. In 
addition, HBV can be divided into eight different genotypes based on the 
genetic variation, and some genotypes could be further divided into several 
subgenotypes. 
1.7.1 HBV genotypes 
The HBV can be divided into eight genotypes based on a genetic 
divergence of 8%, and further separated into subgenotypes with an 
intergroup genomic variation of 4-8% (Norder et al., 2004). Four HBV 
genotypes, A—D, were firstly identified based on 18% intergenotype and 
14% intragenotype genomic divergences, using 18 complete genomes for 
comparison (Okamoto et al., 1988). Later research has identified another 
31 
four HBV genotypes, E-H (Norder et al., 1992; Norder et al., 1994; 
Naumann et al., 1993; Stuyver et al., 2000; Arauz-Ruiz et al., 2002). 
Genotypes A, D and F have been further subdivided into subgenotypes 
(Kramvis et al., 2002; Kimbi et al., 2004; Norder et al., 2003). In addition, 
it is reported that both genotype B and C could be further divided into five 
subgenotypes, and their distribution vary geographically (Nouder et al, 
2004; Chan et al, 2005; Sakamoto et al, 2006). 
The distribution of the virus is strongly associated with ethnicity 
and varies geographically (Lindh et al, 1997; Stuyver et al, 2000; Arauz-
Ruiz etal, 2002) (Figure 1.7.1). HBV genotype A (HBV/A) major exists in 
Europe, Africa and South-east Asia, including the Philippines (Sugauchi et 
al., 2004). HBV/B and HBV/C are predominant in Asia, HBV/D is 
common in the Mediterranean area, the Middle East and India, HBV/E is 
localized in sub-Saharan Africa, HBV/F (or H) is restricted to Central and 
South America and HBV/G has been found in France, Germany (Stuyver 
et al., 2000; Vieth et al., 2002). All these genotypes exist in the United 
States, with frequencies associated with ethnicity (Chu et al., 2003). 
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1.7.2 Predominant genotypes and their subgroups in Asia 
In Asia, genotype B and C HBV are the predominant genotypes. 
Genotype C HBV is associated with more severe liver disease (Chan et al., 
2002; Chan et al., 2003; Kao et al., 2002; Kao et al., 2000), delayed 
HBeAg seroconversion (Chu et al, 2002) and a high risk of HCC 
development (Kao et al., 2003; Chan et al., 2004), as compared to 
genotype B HBV. 
The distributions of subgenotypes have been found to be 
geographically prevalent as well, and some of the subgenotypes have been 
found within only one or two countries. For genotype B HBV, an original 
subgenotype HBV/Ba (B2) is found in most Asian countries including 
China. Other subgenotype B includes: HBV/Bj (Bl) is specifically located 
in Japan, Ba variants HBV/B3 in Indonesia, HBV/B4 in Vietnam and 
HBV/B5 in the Philippines. There are two major subgenotypes for 
genotype C HBV: HBV/Cs (CI) strain is mainly found in Southeast Asia 
including southern China, Vietnam and Myanmar and HBV/Ce (C2) strain 
has been found in East Asia including northern China, Korea and Japan 
(Chan et al., 2005). Three other subgenotypes of genotype C HBV virus 
have been reported: HBV/C5 strain in Vietnam, HBV/C3 strain in 
Polynesia and HBV/C4 strain among the Australian aborigines. In China, 
the majority of HBV isolates belong to subgenotype Ba in genotype B, and 
two subgenotypes in genotype C which are named as Ce and Cs (Huy et al., 
2004, Chan et al., 2005). 
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These subgenotypes of HBV are probably different in terms of 
prevalence of HBeAg and HCC development (Sugauchi et al., 2003; 
Tanaka et al., 2006). Study has shown that HBeAg and the double 
mutation in the basal core promoter (T1762/A1764) were significantly 
more frequent in HBV/Ba than HBV/Bj carriers (Sugauchi et al” 2003). It 
is also reported that Cl/Cs with CI858 might be responsible for a delayed 
seroconversion for the loss of HBeAg in the carriers of Cl/Cs (Chan et al., 
2006). The prevalence of basal core promoter mutations in HBV genotype 
C varies widely among different patient cohorts in different geographical 
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1.7.3 HBV mutations 
The error prone replication system of HBV results in a large pool 
of quasispecies with mutations spread throughout the genome. The rate of 
mutation is estimated to be at 1 x 10'^  to 3 x 10'^  per site per year 
(Okamoto et al., 1987). Under the selection pressure of antiviral drugs 
(e.g., lamivudine, adefovir, or entecavir) or host immune response, HBV 
mutants are selected from the preexisting pool of quasispecies to become 
the dominant species. These mutations may play an important role in viral 
persistence and/or pathogenesis of liver disease. 
Generally speaking, there are two kinds of HBV mutations: those 
selected by natural process and those induced by exogenous pressure such 
as drugs and vaccines. Naturally selected mutants include precore stop 
codon and core promoter mutations that are associated with HBeAg 
seroconversion (Bmnetto et al., 1991; Hamasaki et al., 1994; Okamoto et 
al., 1994), Vaccine escape mutants have been selected due to hepatitis B 
immunoglobulin in liver transplantation and active HBV vaccines. These 
mutants are located at the HBV surface gene, particular at the ‘a’ 
determinant (Carman et al., 1996; Protzer-Knolle et al., 1998; Ghany et al., 
1998; Carman et al., 1990). The most famous one is the mutation at amino 
acid 145 from glycine to arginine (G145R). The drug resistant mutants at 
polymerase gene have been reported among patients who receive long-
term anti-viral treatment. The HBV polymerase gene overlaps the hepatitis 
B surface antigen (HBsAg) in a frame-shifted manner with the result that 
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drug resistant mutations in the HBV polymerase gene can potentially 
affect the nature of HBsAg and its function. Mutations at the tyrosine-
methionine-aspartate-aspartate (YMDD) motif confer the HBV with 
resistance to lamivudine by either changing methionine into isoleucine 
(YIDD) or valine (YVDD) (Bartholomew et al., 1997; Allen et al., 1998). 
1.7.3.1 Precore mutations 
Precore stop codon mutation is a G to A change at nucleotide 
position 1896 (G1896A). This mutation results in a stop codon at codon 28 
and leads to premature termination of precore/core protein and subsequent 
cessation of the production of HBeAg. As the precore region is not 
essential for HBV replication, the viral replication and HBcAg production 
are not affected. The A1896 mutant is frequently selected by the process of 
HBeAg seroconversion. Study has shown that HBV with G1896A is 
replication competent and infectious (Tong et al., 1991). In vitro 
experiment has also found that A1896 could enhance HBV replication 
(Scaglioni et al., 1997). The encapsidation of pregenomic RNA into 
nucleocapsids is dependent on an encapsidation sequence (e), which 
contains a reverted repeated sequence to form a stem-loop structure 
(Figure 1.7.2). The base pairing of stem-loop structure is critical for 
encapsidation and viral replication (Pollack and Ganem 1993; Tong et al., 
1992). The G1896A mutant, together with a G-A mutant at 1899 (glycine-
aspartatic acid, codon 29), will enhance the stability of the "stem" 
structure and thus potentially increase the replication of HBV. The 
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G1899A mutation has been reported to be associated with more severe 
liver disease (Tillman et al., 1995). 
G1896A mutant is usually found in HBeAg-negative patients and it 
has is usually selected as a predominant species during the HBeAg 
seroconversion (Lok et al., 1995; Okamoto et al., 1990; Brunetto et al., 
1991). The mutant is found in anti-HBe positive asymptomatic carriers 
with normal ALT level as well (Okamoto et al., 1990; Turkaspa et al., 
1992; Akarca et al., 1994). The effect of this mutant on causing fulminant 
hepatitis is controversial as the association is found only in some of the 
studies (Carman et al., 1989; Hasegawa et al., 1991; Kosaka et al., 1991). 
It is also reported in some studies that precore stop mutant is associated 
with more severe of liver damage in terms of fibrosis and cirrhosis but not 
related to serum ALT level (Rezende et al., 2005; Grandjacques et al., 
2000; Omata et al., 1991). Although the in vitro studies suggested that 
precore mutant variant has better replicating ability than the wild type 
(Guidotti et al., 1996 and Lamberts et al., 1993), no difference in viral 
replication between the mutant G1896A variant and the wild type has been 
demonstrated using in vivo animal models (Chen et al., 1992). In some 
reports the precore stop codon is even associated with lower viral load 
(Grandjacques et al., 2000). These contradictory findings suggested that 
the replication efficiency in vitro does not necessary reflect the viral load 
in vivo (Chun et al., 2000). 
1.7.3.2 Core promoter mutations 
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The core promoter is located at nucleotide 1742-1849 and it is 
responsible for initiating and regulating the differential transcription of the 
precore and the pregenomic RNAs. This region is referred as basal core 
promoter (BCP). Upstream the BCP region (nucleotide 1634-1742) is 
called core upstream regulatory sequence (CURS) which has a stimulatory 
effect on BCP (Yuh et al., 1992) (Figure 1.7.3). The most common 
mutation within this region is the A1762T and G1764A double mutants. 
The T1762/A1764 dual mutations in BCP can reduce HBeAg production 
by selectively down-regulating the transcription of the precore mRNA 
without affecting the pregenomic RNA (Moriyama et al., 1996; Buckwood 
et al., 1996). In vitro experimental models have shown that the replication 
efficiency is increased by the BCP dual mutations (Scaglioni et al., 1997). 
BCP mutants are commonly found in HBeAg-negative patients 
with chronic active or fulminant hepatitis (Okamoto et al., 1994; 
Nishizono et al., 1995; Sato et al., 1995). The mutants are also found in 
HBeAg positive patients with active liver disease (Okamoto et al., 1994), 
which suggest the BCP mutation only decrease but not completely abolish 
the HBeAg production. Evolution or selection from wild type to mutant 
has been observed during the process of HBeAg seroconversion in 
previous study (Okamoto et al., 1994). Several studies reported an 
association between severity of liver disease and the basal core promoter 
dual mutations (T1762/A1764) (Carman et al.’ 1989; Liang et al, 1991; 
Sato et al., 1995). The dual mutations are also found to be associated with 
HCC development (Baptista et al, 1999; Kao et al, 2003). However, 
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whether these mutations are associated more severe liver disease in 
HBeAg-negative chronic hepatitis B is uncertain. There is also report that 
showed no correlation between the presence of basal core promoter 
mutations and liver disease or HBV-DNA levels in HBeAg-negative CHB 
patients (Chan et al., 2000). 
1.7.3.3 Other mutations associated with clinical outcome 
Some other mutations in the core promoter areas have been found 
to be clinically important. The T to V (non-T) mutation at nucleotide 1753 
(T1753V) in the BCP region and the C to T mutation at nucleotide 1653 
(C1658T) in CURS region have been studied for their association with 
HCC development. Data indicate that C1653T occurs in isolates from 53% 
of HCC sera and may together with T1753V be a useful viral marker for 
advanced liver disease (Takahashi et al., 1998). The two subgenotypes of 
genotype C HBV have specific mutation patterns, which are probably 
responsible for increased carcinogenesis of HBV/Ce (Tanaka et al, 2006). 
A novel nucleotide change from C to T at nucleotide 1485 that 
results in a proline to serine substitution at codon 38 in HBx have been 
reported to be preferentially found in patients with HCC (Muroyamal et 
al., 2006). The detailed mechanism is not clear understood yet. Codons 1-
50 in HBx have been reported to be important for cell transformation 
(Gottlob et al., 1998) and study showed that B-cell epitopes are located in 




the T1485 mutant may represent a strategy on the part of the virus to 
escape immune surveillance. 
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Figure 1.6.1 
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2.1 Aims and Hypothesis 
HBeAg-negative chronic hepatitis B, based on the understanding of 
its epidemiology and natural history, is believed to be a late phase in the 
natural course of chronic HBV infection that develops after HBeAg loss 
and seroconversion to anti-HBe (Hadziyannis, 1995). HBeAg-negative 
chronic hepatitis B has been found as a potentially severe and progressive 
stage of chronic liver disease with very rare spontaneous remissions, 
frequent progression to cirrhosis and increased risk of the development of 
hepatocellular carcinoma (Bonino et al., 1986; Brunette et al., 1991; 
Hadziyannis et al., 1991; Naoumov et al., 1992; Lai et al., 1994). Patients 
suffering from HBeAg-negative active liver disease often indicate an 
abortive effort of immune clearance of the virus (Carman et al., 1995). In 
Asia, 15% of patients are suffering from HBeAg-negative chronic active 
hepatitis (Funk et al, 2002). The HBeAg-negative chronic hepatitis B 
presents a healthy threat with increasing importance no less that of HBeAg 
positive. 
On other hand, the point mutation in core promoter as well as 
precore promoter region is widely accepted to be associated with HBeAg-
negative chronic hepatitis B patients. Precore stop codon mutation (G to A 
at nucleotide 1896, G1896A) and basal core promoter mutations 
(mutations A to T at nucleotide 1762 and G to A nucleotide 1764; A1762T 
and G1764A) are associated with HBeAg loss, but their clinical 
significance to the disease activity in HBeAg-negative chronic hepatitis B 
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is controversial (Lok et al., 1994; Kramvis et al, 1999; Chun et al, 2000). 
Basal core promoter mutations as well as mutations at other sites of the 
HBV genome (at nucleotides 1485, 1653 and 1753) have been described to 
associate with the development of HCC. (Muroyama et al, 2006; Tanaka 
et al, 2006). Whether these mutations are associated more severe liver 
disease in HBeAg-negative chronic hepatitis B is uncertain. 
It is therefore important to study the natural history of these 
HBeAg-negative patients and the clinical significance of these mutations 
within precore promoter and basal core promoter region. As different 
geographical regions have different HBV genotypes/subgenotypes, we aim 
to study the distribution of different HBV genotypes/subgenotypes based 
on a cohort of HBeAg-negative patients from three different parts of China 
(Beijing, Shanghai and Hong Kong). We also investigated the impact of 
HBV genotype/subgenotype and HBV mutations on the severity of 
HBeAg-negative chronic hepatitis B in these patients. The aims and 
hypothesis of the project are as follows. 
2.1.1 Aims 
• To investigate the phylogenetic and virological differences 
between different genotypes/subgroups in different parts of China. 
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• To investigate the impact of HBV genotypes/subgenotypes and 
mutations in the precore/core promoter region on the severity of 
disease in Chinese HBeAg-negative chronic hepatitis B patients. 
• To investigate novel mutations associated with fibrosis and their 
genotypes/subgenotypes prevalence. 
2.1.2 Hypothesis 
• The three cities are different in prevalence of subgenotypes 
distribution. 
• Different viral subgenotype would have clinical impact on the 
virological properties. 
• Mutations at precore and core promoter regions of hepatitis B virus 
may be associated with disease activity among HBeAg-negative 
patients. 
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2.2 Patient Recruitment 
Residual serum samples from chronic hepatitis B patients 
previously participated in a multi-centered, randomized, placebo-
controlled trial of lamivudine were studied (Chan et al, 2006). All patients 
were ethnic Chinese recruited from centers in Hong Kong, Shanghai and 
Beijing. These patients had negative hepatitis B e antigen (HBeAg) for at 
least 6 months prior to screening as well as HBV DNA > 100,000 
copies/mL and elevated alanine aminotransferase levels within 12 months 
of screening. Co-infection with hepatitis C, hepatitis D and human 
immunodeficiency viruses were excluded. Liver biopsy was performed 
within 12 months of screening and samples with at least three portal tracts 
were considered eligible for histologic assessment. Histologic necro-
inflammation was scored using the modified Knodell scoring system (0-18) 
and fibrosis using Ishak scoring system (0-6) by a single histopathologist 
who was unaware of the treatment allocation. 
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2.3 Laboratory Assays 
Serology of hepatitis B, C and D and human immunodeficiency 
virus were measured by commercially available serology assays. HBV 
DNA at baseline was tested by TaqMan real-time PCR assay with a range 
of detection from 100 to 10^ copies as described previously (Chan et al., 
2002). 
2.3.1 Preparation of serum HBV DNA 
HBV DNA was firstly extracted by QIAGEN QIAamp DNA Mini 
Kit (Qiagen Inc., Chats worth，CA) according to the instructions of the 
manufacturer. Briefly, 200|iL of serum was used as starting material and 
lysis with 20|iL QIAGEN protease, 200|iL buffer AL was then added and 
mixed thoroughly to a homogenous solution in order to ensure the 
complete efficient lysis. After incubating at 56°C for 10 minutes, 
centrifuge to remove the drops inside the tube and add 200pL ethanol into 
the tube, mix and centrifuge to remove the drop again. The rest of the mix 
was applied to QIAamp spin column, centrifuge at 6000g for 1 minute and 
remove the flow-through. 500|j,L of buffer AWl was added to the column 
and centrifuge at 6000g for 1 minute again and remove the filtrate. Then 
500|iL of AW2 buffer was applied to the column and after 3 minutes of 
full speed centrifuge (20,000g), remove the flow-through and transfer the 
column to a new tube for elution. 200|aL buffer AE was used for elution at 
49 
6000g for 1 minute. The elution was the purified serum HBV DNA and 
ready for quantification and further experiments. 
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2.3.2 Quantification of serum HBV DNA 
The eluted serum HBV DNA was then be quantified by the 
TaqMdin real-time polymerase chain reaction (PCR) system (PE 
Biosystems, Foster City, CA) (Ryncarz et al., 1999; Loeb et al., 2000). 
PCR primers flanking HBV genome from nucleotide 1549 to 1653 (sense 
primer 5 '-CCGTCTGTGCCTTCTCATCTG and anti-sense 5'-
AGTCCAAGAGTYCTCTTATGYAAGACCTT) and a fluorescent probe 
(5 '-CCGTGTGCACTTCGCTTCACCTCTGC) were used. Each 50mL 
reaction mixture contained lOmL of DNA extract, 833nM concentration of 
each primer, and lOOnM probe. After 2 minutes of incubation at 50 and 
2 minutes of denaturation at 95 the mixture was subjected to 45 cycles 
of PCR at 95 T for 20 seconds and 58 for 1 minute. The intensities of 
the fluorescent dyes in each reaction were read automatically during PCR 
cycling in a PE-Applied Biosystem Detector 7700 machine and the data 
was analyzed by sequence detector software (Version 1.7a; Perkin Elmer, 
Inc., Foster City, CA). Each PCR run contained 2 negative controls and 2 
positive controls, and each sample was run in duplicate. A standard curve 
was generated by serial 10-fold dilutions of EUROHEP hepatitis B virus 
standard (from Dr. K.H. Heerman, University of Goettingen, Goettingen, 
Germany), which contained 2.7 x 10^  viral copies per mL (Fig. 2.2.1). The 
range of HBV DNA detection was from 10^  to 10^  copies/mL with 
correlation coefficient greater routinely than 0.990. The standard curve 
was used to calculate the precise quantities of HBV DNA molecules for 
the unknown samples. 
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Figure 2.5.1 
Standard curve of TaqMan real-time PCR assay 
Serial-diluted HBV DNA samples were compared with the PCR cycle that 
the signal exceeded the negative threshold (Ct). Each sample was run in 
duplicate, and the results for both replicates were shown (black circles) 
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2.4 Full-genome Amplification of HBV DNA 
All HBV DNA extracted from serum samples were kept in a -80°C 
freezer for storage. Full-genome amplification PCR of the HBV genome 
was performed for each baseline serum sample. PicoMaxx High Fidelity 
PCR System (Stratagene La Jolla, CA, U.S.A.) was used for amplification 
of full-genome HBV DNA. Each reaction with a fifty reaction volume 
contains five microliters of extracted HBV DNA template, twenty 
microliters of PicoMaxx reaction mixture, 10 pmol of each amplification 
primer and water. PCR was performed with primer F1 and R7 (Listed in 
Table 2.3.1) with a 5-minute initial denaturation at 95°C, followed by 40 
cycles of amplification (94�C for 40s, 60°C for 30s and 72°C for 4 minutes 
with 30 seconds increase each 5 cycle), and a 7-minute final extension at 
TTC. The amplified PCR products were purified using ExoSAP-IT (USB 
Cleveland, Ohio) following the manufacturer's protocol. Five microliters 
of PCR product was mixed with two microliters of ExoSAP-IT for 
purification reaction in a single tube at 37°C for 15 minutes and then the 
enzyme activity was heat-inactivated for 15 minutes at 80°C. The purified 
product was ready for sequencing PCR. 
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Table 2.4.1 
Primers used for PGR amplification and sequencing of the hepatitis B 
virus genome 
Primer Position，nt nucleotide sequence (5 '-3') Direction 
F1 1821-1841 TTT TTC ACC TCT GCC TAA TCA sense 
F2 2031 -2050 CTC CGG AAC ATT GTT CAC CT sense 
F3 2469-2490 AAG GTG GGA AAC TTT ACT GGG C sense 
F4 3036-3056 TTG GGG TGG AGC CCT CAG GCT sense 
F5 300-318 (T/C)TG GCC AAA ATT CGC AGT C sense 
F6 715-734 CCC CAC TGT (T/C)TG GCT TTC AG sense 
F7 1186-1205 GCT GAC GCA ACC CCC ACT GG sense 
GTT GAT AAG ATA GGG GCA TTT GGT 
R1 2325-2300 antisense 
GG 
R2 2850-2831 CAT GCT GTA G(C/A)T CTT GTT CC antisense 
R3 3217-3197 CCA CTG CAT GGC CTG AGG ATG antisense 
R4 433-412 GAA GAT GAG GCA TAG CAG CAG G antisense 
R5 997-979 TTC (G/T)TT GAC ATA CTT TCC A antisense 
R6 1460-1441 GGG TCG TCC GCG GGA TTC AG antisense 
R7 1825-1806 AAA AAG TTG CAT GGT GCT GG antisense 
GenBank accession number of the referent sequence: NC—003977 
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2.5 Full-genome Sequencing of HBV DNA 
The purified full-genome PGR products were used for direct 
double-strand sequencing by BigDye Terminator v3.1 Cycle Sequencing 
Kit (AppliedBioInformatics, Foster City, CA, U.S.A.). Briefly, one 
microliter of purified PCR product (Full-genome HBV DNA) was used as 
reaction template together with two microliters of Ready Reaction Premix, 
one microliter of BigDye Sequencing Buffer, 3.2 pmol of sequencing 
primer (Primer list is shown in Table 2.3.1 and the position of all 14 
primers is shown in Figure 2.4.1) and water in a single reaction of ten 
microliters. The sequencing reaction was carried out in the standard 
condition with a 1 -minute initial denaturation at 96°C, followed by 25 
cycles of amplification (96°C for lOsec, 50�C for 5sec and 60�C for 4 
minutes in each cycle) and rapid thermal ramp to 4°C. The product was 
kept under 4°C until ready to purify. The sequencing products were 
purified by DyeEx 96 Kit (QIAGEN). Briefly, the DyeEx 96 plate was 
firstly placed on top of the collection plate with the up and bottom tape 
sheets removed, and centrifuged for 3 minutes at 900g to remove the 
buffer within the wells. Then the DyeEx 96 plate was put on top of elution 
plate with appropriate adaptor and samples (Sequencing products) could 
be applied to the individual wells. Centrifuge at 900g for another 3 
minutes would elute the purified product. Each purified product was mixed 
with 10 |jL HiDi formamide loading buffer and placed in a single well of 
the 96-well plate for loading into the ABI3100 sequencer. For ABO 100 
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sequencer, the 36cm capillary and P0P4 polymer gel were used and ABI 
data collection (VI.1) was used for analyzing the raw sequencing data. 
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Figure 2.5.1 
Primer position for full-genome sequencing 
M ^ - " F ^ ^ FR F6 F7 ^ 
_ r - HBV full-genome DNA (3.2kb)诚 
R7 R5 R4 R3 ’ 考 R? R1 
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2.6 Assembly of HBV Full-genome Sequence 
The nucleotide sequences of the amplified HBV DNA were 
analyzed and assembled into full-genome sequence by SeqScape 
(Version2.0, ABI). Each sequencing reaction read by the sequencer 
produced a sequence file consisted nucleotide sequence about 500~600bp 
long. The sequencing file were then read and edited by SeqScape, resulted 
a sequence fragment ready for further analysis. For each patient, 14 
fragments of such nucleotide sequence fragments were put together in a 
specimen in the SeqScape program. A consensus sequence of the HBV 
isolate was then made by SeqScape via multiple-alignment of these 
nucleotide sequence fragments. The consensus sequence was double 
checked manually with the chromatography to avoid misreading or 
missing of nucleotide sequence. As the primer set consisted of primer in 
both sense and anti-sense direction, the full-genome sequence could be 
verified in both directions. The HBV full-genome sequences were 
determined and extracted in txt format for importing into CLUSTALW for 
further analysis. 
58 
2.7 Phylogenetic Analysis 
2.7.1 Construction of phylogenetic tree 
The fUll-genome nucleotide sequences of the HBV isolates were 
compared with 50 reference sequences from 8 HBV genotypes (A-H) as 
well as all 10 subgenotypes in genotype B and C retrieved from GenBank. 
All reference sequences from GenBank were retrieved from patients with 
HBeAg-negative chronic hepatitis B. The geographical origins of patients 
harboring different HBV genotypes in GenBank were retrieved from 
perspective original publications and descriptions in the GenBank database. 
The HBV genomic sequences were multiple aligned using CLUSTALW 
software (Thompson et al, 1994). The genetic distances were estimated by 
Kimura's 2-parameter's method and phylogenetic trees were constructed 
by the neighbor-joining method (Kimura, 1980; Saitou et al, 1987). The 
reliability of the phylogenetic tree analysis was assessed and assured by 
bootstrap resampling with 1000 replicates. Phylogenetic and molecular 
evolutionary analysis was performed using MEGA (Version 3.1) (Kumar 
et al, 2004). 
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2.7.2 Genotype and subgenotype determination 
Using reference sequence as reference in the phylogenetic tree, 
genotypes and subgenotypes can be identified (The list of reference 
sequences are shown in Table 2.7.1). The genotyping is confirmed by 
Mega based on an intergroup nucleotide sequence divergence >8%. 
Subgrouping of genotype B (Ba and Bj) and C HBV (Cs and Ce) was 
based on an intersubgroup difference of nucleotide sequence of >4% 
(Chan et al, 2005, Sugauchi F, 2002). 
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Table 2.4.1 
The list of reference sequences in this study 
Accession Accession 
number Courntry of discovery number Courntry of discovery 
AB106564 Ghana AF384371 China 
X75664 Senegal AF384372 China 
X02496 Russia AF182802 China 
X65257 Italy D23681 Japan 
AF 160501 France DQ089799 HongKong 
AF 121246 Vietnam DQ089797 HongKong 
AB073826 HongKong D23684 Japan 
AB073837 Japan X04615 Japan 
AB073827 HongKong AY247031 Korea 
AY217366 China AY040627 China 
AB073850 Japan AY247032 Korea 
AB073852 Japan Y18856 China 
AY033072 Vietnam AB115417 Okinawa 
AY033073 Vietnam AB115418 Okinawa 
AB033554 Indonesia AB241112 Philippine 
AB033555 Sumatra AB241113 Philippine 
AB241116 Philippine X75656 Polynesia 
AB241117 Philippine X75665 NewCaledonia 
AF223955 Vietnam AB048704 Australian 
AY217372 China AB048705 Australian 
AF223961 Thailand M57663 Philippines 
AY217375 China X70185 Europe 
AB 112408 Myanmar X75658 France 
AB074047 Thailand X75663 SouthAmerica 
AB 117758 Cambodia AY090454 Nicaragua 
61 
2.8 HBV Mutations 
Seven "hot-spot" mutation sites were studied for their association 
with disease activity in HBeAg-negative chronic hepatitis B. All these 
mutations have been previously reported to be associated with HCC 
development and/or severe liver diseases (Lok et al., 1991; Muroyama et 
al., 2006; Tanaka et al” 2006; Sugauchi et al., 2003; Kuang et al., 2004; 
Chan et al., 2000). Figure 2.8.1 shows the positions of these mutation sites 
in the HBV viral genome. All the seven mutations were located at the X 
and precore regions of the HBV genome. 
Novel HBV mutations associated with severe liver fibrosis were 
selected for study. Severe liver fibrosis was defined as Ishak score of > 4 
(of 6) (Liaw et al., 2004). These mutations were selected by information 
gain criterion, which was designed to reduce the number of features used 
in classification while maintaining acceptable classification accuracy (see 
appendix). The features were ranked by the information gains, and then the 
top ranked features were chosen for classification. A site with higher 
information gain would contribute more in the classification such that 
more samples could be distinguished by this site. In our study, the top five 
mutations site with highest information gain, i.e. the sites with biggest 
difference between patients with mild versus severe liver fibrosis, were 
selected for analysis. 
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Figure 2.8.1 
Hot-spot mutation sites in the HBV genome 
> f r 
I 1903 ^ 1376 
B C P N 丁 1 7 6 2 & ^ N T 1753 「 N T 1 6 5 3 
NT1764 
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2.9 Info-gain program 
Information gain was a common criterion for feature selection. The 
information gain of a feature (attribute) was the uncertainty (entropy) that 
could be reduced if the attribute was used for classification. Hence, the 
information gain should be the higher the better. Equation 1 was the 
entropy E’ of an attribute X with n values Xi,,,X„, and P{Xj) is the 
probability of the value Xj . 
7=1 
Specific to a typical DNA classification problem, we assumed the 
data had M classes Ci",Cm. For each aligned site position, it has N 
possible nucleotides Vi",Vn. We defined \Cnt\ as the number of sequences 
in Class Cm. \Cnii\ was the number of sequences in Class Cm whose 
character at the aligned site is Vi, which could be A, T, G or C in our case. 
The Reminder of X, R{X) was defined as follows: 
N y ^ c , I 
m = z t u (2) 
'=0 J Ck I 
Information Gain IGj of the aligned site j was the difference 
between the original information content E(C) of the data set and the 
amount of information needed to classify all the unclassified data left in 
the data set after applying site j for classification: 
IGj =E{C)-R{j) (3) 
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2.10 Statistical Analysis 
All statistical analyses were performed by the Statistical Program 
for Social Science (SPSS 11.5 for windows, SPSS Inc., Chicago, IL). The 
geographical distribution of genotype/subgenotype was analyzed by Chi 
square test. To compare different demographic and clinical parameters, 
several statistical methods were used. When compare the parameters 
between three subgenotypes, ANOVA was used to assess the age, body 
mass index (BMI)，Log HBV DNA, serum albumin, prothrombin time (PT) 
and serum ALP level of patients; while Kmskal-Wallis H test was 
employed to test the alanine aminotransferase in terms of times of the 
upper limit of normal (ALTXULN), total bilirubin, necro-inflammation 
(Nl-score) and fibrosis score (F-score). When compare these parameters 
between genotypes or each two subgenotypes, student T test was used 
instead of Anova test and Mann-Whitney U test replaced the Kruskal-
Wallis H test. Same tests were used to assess these parameters between the 
mutant and the wild type at a single nucleotide position. Linear regression 
was used to test the effects of different HBV genotype/subgenotype and 
HBV mutants on the biochemical, virological and histological severity of 
liver disease. All statistical tests were two-sided. Statistical significance 
was taken as p<0.05. 
Statistical analyses were firstly used to compare the demographic 
and clinical parameters between genotype B and C patients at the baseline. 
A further analysis was done to compare these parameters between the 
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three subgenotypes. For parameters that showed significant difference, 
comparisons between each two subgenotypes were done to see if 
subgrouping of virus would affect the clinical outcome of disease. 
Statistical tests were done between mutant and wild type to see the effects 
of a single nucleotide difference on the clinical outcome as well. Both hot-
spot mutations and novel mutation sites selected by Info-gain program 





3.1 Patient Information 
One hundred and thirty-nine patients were recruited in the clinical 
study. One hundred and one patients had residual serum samples available 
for full-genome amplification and sequencing analysis of HBV. Overall, 
there were 84 male and 17 female patients with aged 42士 10 years. The 
body mass index (BMI) was 23.66±3.51 kg/ml The log HBV DNA was 
6.39士0.95 copies/mL and the alanine aminotransferase (ALT) was 1.85 
(range 0.22-13.03) times the upper limit of normal (x ULN). Among 84 
patients who had adequate liver biopsy sample for histologic assessment, 
the median necro-inflammation score was 5 (range 0-12) and the fibrosis 
score was 1.5 (range 0-6). 
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3.2 Phylogenetic Analysis 
A phylogenetic tree was plotted to show to phylogenetic 
relationship among 101 chronic hepatitis B isolates sequences and 50 
reference sequences (Figure 3.2.la�Figure 3.2.Id). On phylogenetic 
analysis of the complete HBV genome, thirty-six (36%) patients were 
infected by HBV genotype B and 65 (64%) patients were infected by HBV 
genotype C. Among the 65 isolates of HBV genotype C, 19 (29%) isolates 
could be classified as Cs subgenotype and the remaining 46 (71%) isolates 
as Ce subgenotype. Three HBV genotype B isolates that formed an out-
group cluster had intergroup nucleotide sequence difference with 
subgenotype Ba less than 4% and they were defined as subgenotype Ba in 
the subsequent analysis. All other HBV genotype B isolates could also be 
classified as Ba subgenotype and we did not have subgenotype Bj HBV in 
our patients. The nucleotide sequence differences among different HBV 
genotypes and subgenotypes were shown in Table 3.2.1. 
The geographic distributions of the three HBV subgenotypes were 
shown in Table 3.2.2. Genotype B HBV was present in 19 of 45 (42%) 
patients in Hong Kong, 12 of 31 (39%) patients in Shanghai and 5 of 25 
(20%) patients in Beijing (Chi square for trend p=0.16). Almost all (38 of 
39 isolates, 97%) HBV genotype C in mainland China (Shanghai and 
Beijing) belonged to subgenotype Ce whereas 18 of 26 (69%) of HBV 
genotype C in Hong Kong belonged to subgenotype Cs (p< 0.001). 
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Figure 3.2.1a 
Phylogenetic tree of 101 HBV genome sequences from the studied cohort 
and 50 selected HBV sequences from GenBank. Detailed phylogenetic 
trees of HBV subgenotypes Cs, Ce and Ba are shown in Figures 3.2.1b, 
3.2.1c and 3.2.Id, respectively 
f ^ l 
r - AB241112 Philippina _ 
C5 
9 9 I - AB241113 Philippine _ 
91 X75656 Polynesia 1 
— 3 3 丨 X75665 NewCaledonia J 
~ AB048704 Aboriginal Australian "I 
gg 93LaB0487 ( ] 5 Aboriginal Australian J 
39 |— • 40377 
I — — • 4 0 3 6 5 
• 40397 
98 331— AB033554 Indonesia "I 
97 I— AB033555 Sumatra J 
80 「AB241116 Phili|3pine 1 
^ AB241117 Philippine J 
38 _ 991 AB073850 Japan "j . 
30 J n AB073852 Japan J ‘ 
「 AY033072 Vietnam "I 
B4 
99L AYD33073 Vietnam 
I— J 
L ^ Ba 
M57663 Philippines 1 
X70185 Europe 
_ ^ AB106564 Ghana 1 
X75664 Senegal J 
99 X02496 Russ ia 1 
D 
33 X65257 Italy . 
AF160501 France ] G 
AY090454 Nicaragua ] H 
^ X75658 France 1 





Expanded phylogenetic tree for HBV subgenotype Ce 
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Figure 3.2.1c 
Expanded phylogenetic tree for HBV subgenotype Cs 
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Expanded phylogenetic tree for HBV subgenotype Ba 
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Table 3.2.1. 
The inter-genotype and inter-subgenotype nucleotide sequence difference 
o/oof 
nucleotide 
difference Ce Cs A D E F G H 
Ba 6.00 7.60 8.80 10.00 10.80 13.70 12.20 14.30 
Ce - 4.00 8.10 8.90 9.40 12.9 11.40 13.20 
Cs - - 8.70 9.90 10.90 14.00 12.30 14.10 
The differences between genotype / subgenotype are shown in this table in 




The geographic distribution of three subgenotypes, in term of number of 
isolates 
Ba ^ ^ 
Number of 
36 46 19 
patients 
Hong Kong 19(53%) 8(17%) 18 (95%) 
Shanghai 12 (33%) 18 (39%) 1 (5%) 
Beijing 5 (6%) 20 (43%) 0 (0%) 
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3.3 HBV Genotype/Subgenotype 
There was no difference in the demographic and clinical 
characteristics between patients infected by HBV genotype B (n=36) and 
C (n=65) (Table 3.3.1). When patients infected by different HBV genotype 
C subgroups were considered, there were significant differences in age, 
body mass index (BMI), serum albumin, total bilirubin and prothrombin 
time among the three patient groups (Table 3.3.2). The difference in serum 
alanine aminotransferase (ALT) and histologic necro-inflammation just 
fell short of statistical significance. There was no difference in HBV DNA 
levels, histological fibrosis among the three patient groups. 
The mean values in total bilirubin and prothrombin time of the 
three patient groups were well within the normal ranges and were probably 
insignificant in terms of clinical outcome. Therefore I will ignore these 
two parameters in the further analysis. Patients infected by HBV 
subgenotype Cs had lowest serum albumin (vs Ba p二0.01, vs Ce p<0.01) 
and higher ALT (vs Ba, p=0.02; vs Ce, p=0.03) (Table 3.3.2). Patients 
infected by HBV subgenotype Cs also had more severe histologic 
necroinflammation than that of patients infected by HBV subgenotype Ce 
(p=0.03), but the difference with that of patients infected by HBV 
subgenotype Ba was not significant (p二0.08). Patients infected by HBV 
genotype Ce appeared to be youngest in age (vs Ba, p=0.04; vs Ce, 
p=0.01). After adjustment of age and gender by multivariate analysis, the 
difference between subgenotypes Cs and Ce on ALT and necro-
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inflammation score just fell short of statistical significance (p=0.076 for 
necro-inflammation and p= 0.068 for serum ALT). 
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Table 3.2.1. 
Comparison of clinical parameters between patients with HBV genotypes 




Number of patient 36 65 
Age (year) 42.7士 10 40.3±9 0.22 
Male (%) 32(89%) 52(80%) 0.26 
Body mass index 
2 3 . 9 ± 3 . 0 23.5士 3.8 0 . 5 4 
(kg/m2) 
HBV DNA (copies/mL) 6.4士 1.0 6.4士0.9 1.00 
Albumin (g/1) 42.4±4.4 42.6±4.9 0.86 
Alkaline phosphatase 
85.3 士 23.6 88.7±31.0 0.57 
(IU/1) 
Bilirubin Oimol/l) 12.0(6.0-27.8) 14.0(3-135) 0.57 
Prothrombin time 
12.2±1.4 12.5±1.6 0.51 
(second) 
Alanine 
aminotransferase 1.67(0.23-5.76) 1.97(0.22-13.03) 0.31 
(xULN) 
Necro-inflammatory 
5(1-11) 5(0-12) 0.90 
score 
Fibrosis Score 1(0-6) 2(0-6) 0.87 
ULN = Upper limit of normal 
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Table 3 . 2 . 1 . 
Comparison of clinical parameters between patients with different HBV 
subgenotypes using ANOVA test 
^ ^ ^ P Value 
Number of 
36 46 19 
patient 
Age (year) 42.7±10 38.4±9 45±9 0.02 * 
Male (%) 32(89%) 35(76%) 17(89%) 0.22 
Body mass 
23.9±3.0 22.6士2.8 25.5±4.9 0.01 * 
index (kg/m ) 
HBV DNA 
6.4±1.0 6.4 士 1.0 6.4 士 0.5 1.00 
(copies/mL) 
Albumin (g/1) 42.4士4.4 44.0±4.8 39.2士3.3 <0.01 * 
Alkaline 
phosphatase 85.3±23.6 84.5±28.6 98.6±34.9 0.17 
(IU/1) 
Bilirubin 12.0(6.0-
14.8(4.0-135.0) 10.0(3-16) 0.02 * 
(limol/1) 27.8) 
Prothrombin 




aminotransferase 0.05 * 
5.76) 13.03) 11.44) 
(xULN) 
Necro-
inflammatory 5(1-11) 4(0-12) 7(2-10) 0.08 
score 
Fibrosis Score 1(0-6) 1(0-6) 2(1-6) 0.33 
ULN 二 Upper limit of normal, p value with * is significant in the analysis 
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3.4 "Hot-spot" HBV Mutants 
The clinical characteristics of patients infected by HBV with and 
without the seven selected "hot-spot" mutations at nucleotides 1485, 1653, 
1753, 1762, 1762, 1896 and 1899 were shown in Table 3.4.1. Mutation of 
T to V at nucleotide 1753 (T1753V) was associated with higher ALT level 
and lower HBV DNA level. Mutations of A to G at nucleotide 1764 
(G1764A) and G to A at nucleotide 1899 (G1899A) were also associated 
with lower HBV DNA levels. There was no significant difference in the 
histologic necro-inflammation and fibrosis scores among patients with 
infected by wild type or mutant HBV at these nucleotides positions. 
In the study we also investigated the prevalence of these hot-spot 
mutations in different genotypes / subgenotypes. The results are shown in 
Table 3.4.2. There was no difference for the prevalence of mutants at 
nucleotide 1485 and 1899 among different HBV genotypes or 
subgenotypes. Mutation G1896A was more frequently in genotype B than 
genotype C (p=0.001), and prevalence of this mutant in subgenotype Cs 
was significant lower than subgenotype Ce (p<0.001) or Ba (p<0.001). For 
the mutations C1653T, T1753V, A1762T and G1764A, the prevalence 
was significant higher in HBV genotype C than HBV genotype B 
(p=0.015 for C1653T, p=0.001 for T1753V and p<0.001 for A1762T and 
G1764A). No difference in prevalence was observed between subgenotype 
Ce and Cs in these four mutants. 
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Table 3.4.1. 
Histologic and virological features of wild type and HBV mutants v 
various hot-spot mutations. Log HBV DNA is shown by meaniSD. Otl 
parameters are shown by median (range) as they are not norma 
distributed 
Histological Parameters 
Nucleotide 、丁 . Necro . 
N inflammatory p Fibrosis score p 
score 
G 72 5(0-12) 2(0-6) 
A 12 5(1-9) 3(0-6) 
1753 T 62 5(0-10) 0.14 2(0-6) 0.24 
V 22 6(0-12) 3(0-6) 
1762 A 30 5(1-11) 0.64 3(0-6) 0.54 
T 53 5(0-12) 2(0-6) 
1764 G 23 6(1-11) 0.30 3(0-6) 0.52 
A 60 5(0-12) 2(0-6) 
1653 C 68 5(0-12) 0.40 2(0-6) 0.79 
T 16 6(0-10) 2(0-6) 
1896 G 39 5(0-10) 0.69 2(0-6) 0.83 
A 45 5(1-12) 2(0-6) 
1485 C 78 2(0-6) 0.75 5(0-12) 0.75 
T 6 3(0-6) 5(0-10) 
Virological Parameters 
1 Log HBV 
Nucleotide 、丁 t tt xt\ 二t a 
N ALT (xULN) p DNA p 
(copies/mL) 
G 86 2.46(0.22-11.44) 6.45土0.99 0.02 * 
A 15 2.54(0.23-13.03) 6.05土 0.50 
1753 T 77 2.09(0.22-5.53) 0.030 * 6.52土0.95 0.014 * 
V 24 3.70(0.23-13.03) 5.98±0.82 
1762 A 37 2.20(0.65-5.98) 0.56 6.52士 1.00 0.30 
T 63 2.63(0.22-13.03) 6.31 士 0.91 
1764 G 30 2.37(0.65-5.98) 0.93 6.67士0.89 0.048 * 
A 70 2.51(0.22-13.03) 6.26士0.95 
1653 C 79 2.44(0.23-11.44) 0.67 6.44土0.92 0.35 
T 22 2.56(0.22-13.03) 6.22土 1.05 
1896 G 50 2.59(0.22-13.03) 0.67 6.50士0.89 0.26 
A 51 2.35(0.23-11.44) 6.29士 0.99 
1485 C 92 1.89(0.22-11.44) 0.56 6.41 土0.92 0.55 
T 9 1.28(0.73-13.03) 6.21 土 1.20 
ULN 二 upper limit of normal, p value with * is significant in the analysis 
Table 3.2.1. 
The number of mutants appeared in different genotypes / subgenotypes 
and the percentage of mutant within the total patients in those genotypes / 
subgenotypes 
Ba ^ ^ C 
Number of patients 36 46 19 65 
014851 1(30/0) 6(13%) 2(11%) 8 (12%) 
C1653T 3 (8%) 16(35%) 3 (16%) 19 (29%) 
T1753V 2 (6%) 13 (28%) 9 (47%) 22 (34%) 
A1762T 15 (42%) 32 (70%) 16 (84%) 48 (74%) 
G1764A 16 (44%) 38 (83%) 16 (84%) 54 (83%) 
G1896A 26 (72%) 24 (52%) 1 (5%) 25 (38%) 
G1899A 6(170/0) 7(15%) 2(11%) 9 (14%) 
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3.5 HBV Mutation Associated with Liver Fibrosis 
3.5.1 Mutant selection 
The info-gain score is determined by the info-gain program and the 
value shows the contribution of a single nucleotide to the differences 
between the two groups of patients, that is, the group with severe liver 
fibrosis and that with mild liver fibrosis. 
Five mutation sites with high info-gain score (i) had been selected 
in this study: 2289A (i=0.1024), 2858C (i=0.0885), 1221G (i-00839), 
3208A (i=0.0602) and 220IC (i=0.0578). All these five mutants cause 
amino acid substitution in the HBV proteins, as shown in Table 3.5.1. 
Therefore they were selected to test if these changes in the protein 
sequence would lead to significant differences in terms of clinical 
parameters in the patients. The other nucleotide positions were not selected 
as their info-gain values were quite low and probably would not lead to 
any significant differences in clinical outcome of patients. 
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Table 3.2.1. 
The position in the HBV coding sequence and the info-gain value of the 
novel mutants associated with liver fibrosis 
Nucleotide i-value Location 
0.1024 ^ 
2858 0.0885 P/Pre-Sl 
1221 0.0839 P 
3208 0.0602 P/Pre-Sl 
2 m 0.0578 Core 
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3.5.2 Clinical significance of novel mutants 
The clinical characteristics of patients infected by HBV with and 
without mutations at these sites are shown in Table 3.5.2 and Table 3.5.3. 
Three of the five mutation sites (nucleotides 2289, 2858 and 2201) were 
associated with statistical difference in severity of liver fibrosis. Mutation 
of C to A at nucleotide 3208 (C3208A) was associated with more severe 
necro-inflammation but the impact on fibrosis fell short of statistical 
significance. None of the mutation sites were associated with older age or 
higher HBV DNA levels. 
Mutation of T to C at nucleotide 2201 (T2201C) was associated 
with less severe necro-inflammation and fibrosis than the wild type vims. 
Twenty-one of 46 (45.7%) patients infected by HBV subgenotype Ce had 
T2201C mutation whereas none of the patients infected by HBV 
subgenotypes Cs (p=0.001) and Ba (p< 0.001) had this mutation. Mutation 
of G to C at nucleotide 2858 (G2858C) was associated with higher ALT 
levels and more severe fibrosis. Two of 46 (4.4%) patients infected by 
HBV subgenotype Ce, 2 of 19 (10.5%) patients infected by HBV 
subgenotype Cs and none of the 36 (0%) patients infected by HBV 
subgenotype Ba had G2858C mutation. Mutations of C to A at nucleotide 
2289 (C2289A) was associated with severe fibrosis but not necro-
inflammation. C2289A mutation was predominantly found among patients 
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Table 3.2.1. 
Histologic parameters of wild type and HBV mutants associated with liver 
fibrosis selected by info-gain program. Parameters are shown by median 
(range) as it is not normally distributed 
Necro-
inflammatory Fibrosis 
Nucleotide N score p score p 
A / T / C 7 8 5(0-12) 046 2(0-6) 0.22 
G 6 6(2-9) 3(1-5) 
2858 G 79 5(0-12) 0.22 2(0-6) 0.033 * 
C 4 7(5-9) 5(4-5) 
2289 C 75 5(0-12) 0.13 2(0-6) 0.021 * 
A 6 7(1-10) 4(2-5) 
3208 C 80 5(0-12) 0.006 * 2(0-6) 0.087 
A 4 9(7-10) 4(1-6) 
2201 T 61 6(0-12) 0.002 * 3(0-6) 0.002 * 
C 21 3(0-7) 1(0-5) 
p value with * is significant in the analysis 
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Table 3.2.1. 
Virological features of wild type and HBV mutants associated with liver 
fibrosis selected by info-gain program. Log HBV DNA is shown by 




Nucleotide N ALT (xULN) p (copies/mL) p 
2.42(0.22-
1221 A/T/C 92 13.03) 0.11 6.39±0.95 0.9 
3.08(1.24-
G 8 5.26) 6.43±0.98 
2.35(0.22- 0.008 
2858 G 94 11.44) * 6.40±0.97 0.58 
6.15(3.22-
C 4 13.03) 6.13 士 0.34 
2.51(0.22-
2289 C 90 13.03) 0.84 6.37 士0.98 0.26 
2.19(1.05-
A 7 5.26) 6.80±0.59 
2.45(0.22-
3208 C 96 13.03) 0.52 6.40±0.96 0.73 
2.81(1.10-
A 4 5.53) 6.23士 0.77 
2.60(0.23-
2201 T 75 13.03) 0.23 6.42士 0.91 0.86 
2.19(0.22-
C 23 7.02) 6.3壯1.06 





4.1 Full-genome Sequencing Strategy 
Nowadays, it is widely accepted that the phylogenetic relationship 
could be drawn from the sequence of S gene region of HBV viral genome. 
However, in our study we chose to sequence the full viral genome. The 
full-genome sequencing strategy will definitely increase a lot of lab work, 
which is a major drawback to use it constructing the phylogenetic tree. The 
advantage of this method, however, is to provide much more detailed 
information in the genome than just sequencing the S gene region. In this 
study, we want to analyze the clinical impact of hot-spot mutations and 
novel mutations associated with liver fibrosis. Therefore it is important to 
extract these sequence information from the HBV isolates. Simply 
sequence the S gene will not provide information in the BCP and precore 
promoter region, and the power of info-gain program will be limited. 
Therefore, full-genome sequencing is useful and important in our study to 
perform further analysis. 
The error rate of polymerase used in the sequencing kit is one 
single nucleotide substitution out of 9000. Therefore the reliability of the 
sequencing reaction is a major concern of the study as well. It is therefore 
important to employ the two-direction sequencing method. By sequencing 
the same nucleotide from 5' and 3' directions at least for one time, the 
potential sequencing error caused by the polymerase will be minimized 
and the results of full-genome sequencing are therefore worth trusting. 
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4.2 HBV genotypes/subgenotypes Distribution and Disease Activity 
In this study, we have identified the phylogenetic and clinical 
differences of HBV among HBeAg-negative chronic hepatitis B patients in 
three different parts of China. HBV subgenotype Cs, which was associated 
with more severe disease activity and found almost exclusively in the 
Hong Kong cohort, may explain the more severe HBeAg-negative liver 
disease in this location than Shanghai and Beijing. 
4.2.1 HBV genotype/subgenotype distribution 
In this study, the phylogenetic analysis of 101 full genome 
sequences showed that patients in China fall into two genotypes: HBV/B 
(36%) and HBV/C (64%). All genotype B viral isolates belong to 
subgenotype Ba and isolates in genotype C fall into two subgenotypes 
respectively: HBV/Cs (29%) and HBV/Ce (71%). The results obtained in 
the study verify the previous opinion that subgenotype Cs is almost 
exclusively concentrated in the Southern China whereas Ce accounts for 
most genotype C patients in the Northern China (Chan et al, 2005). 
Although the sample size of this study is limited, the geographical 
distribution of subgenotypes in genotype C is quite distinguished. The 
significant differences in the geographic distribution of subgenotypes 
suggested a general distributing pattern of HBV subgenotypes in China. 
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4.2.2 Clinical significance of HBV genotype/subgenotype 
It is well accepted that HBV genotype B is associated with early 
HBeAg seroconversion and HBV genotype C is related to a more severe 
liver disease (Chu et al., 2002). However, in our study the HBV genotypes 
B and C HBeAg-negative chronic hepatitis B patients did not show 
significant differences in terms of clinical and virological difference at 
baseline. This is probably because we have only studied patients with 
HBeAg-negative chronic hepatitis B. Those patients who have active 
disease with HBeAg-positive have not been studied, and genotype C HBV 
is associated with more active liver disease in the HBeAg-positive patients 
and delayed HBeAg seroconversion (Chan et al., 2003; Chu et al., 2002). 
On HBV subgenotype comparison, our data showed that HBV 
subgenotype Cs had significant higher ALT levels as well as lowest 
albumin levels compared to other two HBV subgenotypes. The necro-
inflammation associated with HBV subgenotype Cs was also more severe 
than that of HBV subgenotype Ce. This result suggested that HBV/Cs 
HBeAg-negative chronic hepatitis B patients in China showed a more 
severe liver disease. Although this difference cannot be directly 
extrapolated to the risk of HCC and cirrhotic complications as HBeAg-
positive patients were not studied, HBV subgenotype Cs seemed to have 
more severe liver disease even after HBeAg seroconversion. This 
observation may explain the geographical differences of active HBeAg-
negative hepatitis between different parts of Asia. It would be interesting 
91 
to perform similar studies in Europe to see if similar pattern could be 
obtained; as the difference in disease activities associated with different 
HBV genotype/subgenotypes may explain the high prevalence of HBeAg-
negative chronic active hepatitis B in the Mediterranean countries 
(Fattovich, 1986). 
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4.3 HBV Hotspot Mutants and Disease Activity 
Though many HBV mutations have been reported to be associated 
with HCC development, the exact role played by hot spot mutations in 
HBeAg-negative patients is uncertain. Nucleotide 1753 is located in the 
nucleotide region 1751 to 1778 which contains the binding site of multiple 
liver-enriched transcription factors, including the hepatocyte nuclear factor 
4 that has been shown to up-regulate the transcription from the BCP 
(Raney et al., 1997). Mutation VI753 has been reported to be associated 
with severe liver diseases and progression from chronic liver disease to 
HCC development (Tanaka et al., 2006). Data in our study showed that 
mutation T1753V was associated with higher ALT level, which suggested 
this mutant might cause more severe liver disease in HBeAg-negative 
patients. This observation is in agreement with that of other investigators 
and may explain the association between 1753 mutant and HCC 
development (Otaka et al., 1993; Kidd-Ljunggren et al., 1997). 
The G1899A mutant is located within an encapsidation sequence (s) 
that is crucial for HBV encapsidation and replication (Pollack et al., 1993; 
Tong et al., 1992). The 1899 mutation, together with precore stop mutation 
at nucleotide 1896 will increase the replication of HBV. The T1762/A1764 
dual mutations in basal core promoter can prevent HBeAg production by 
selectively down-regulate the transcription of the precore mRNA without 
affecting the pregenomic RNA (Moriyama et al., 1996; Buckwood et al., 
1996). It has been reported that the replication efficiency is increased by 
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the dual mutation (Scaglioni et al., 1997). Studies demonstrated in vitro 
that these mutations not only cease/decrease HBeAg production but also 
increase HBV replication (Parekh et al., 2003; Baumert et a l , 1996; 
Buckwood et al., 1996). In our study, the G1899A and T1764A mutants, 
together with the T1753V mutant, were found to be associated with lower 
viral load. As previously reported, the replication efficiency does not 
necessarily predict the viral load (Chun et al., 2000). This paradoxical 
phenomenon may be related to the increased host immune response to 
these mutants, which eventually may lead to a lower viral load in the body. 
Mutant at core promoter associated with lower viral loads suggested 
mutations at this region have implication on viral replication. However, 
the exact mechanism is still uncertain and the discovery needs further 
investigation. 
Though reports have suggested the HBV subgenotypes Ce and Cs 
have different pattern of mutants (Tanaka et al, 2006)，we did not find any 
significant difference in term of prevalence of mutations except the 
precore stop codon mutation G1896A. HBV subgenotype Cs is associated 
with CI858，which prevented the development of G1986 due to the stem-
loop structure of the encapsidation sequence (Chan et al., 2005). Therefore, 
even though we were studying HBeAg-negative chronic hepatitis B, the 
prevalence of precore stop codon mutation among HBV subgenotype Cs 
was very low. Nonetheless, the prevalence of G1896A mutation among 
HBV genotypes B and Ce were only 72% and 52%, respectively. This is 
because some patients underwent HBeAg seroconversion by development 
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of basal core promoter mutations (A1762T and G1764A). This virological 
difference can explain the geographical difference in the prevalence of 
precore stop codon mutations in different parts of China. 
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4.4 HBV Novel Mutants 
Novel mutants have been found by info-gain program based on the 
grouping of fibrosis. Three novel HBV mutation sites associated with liver 
fibrosis among HBeAg-negative chronic hepatitis B have been identified 
in our study. 
The T2201C mutation is located within the core region and it is 
protective against liver fibrosis. Mutations C2289A and G2858C are 
associated with more severe liver fibrosis. The C2289A mutation is 
located within the core protein, while the G2858C mutation is located 
within the Pre-Sl region which bears the hepatocyte binding site. The 
association of T2201C mutation with HBV subgenotype Ce may partly 
explain the milder disease activity than that of HBV subgenotype Cs, as 
this mutation is exclusive in subgenotype Ce. The prevalence of C2289A 
and G2858C mutation are too low for any concrete conclusion to be drawn. 
Further larger-scaled studies are needed to confirm the relationship of 
these mutations with liver fibrosis. Experimental work is also wanted to 
determine basic mechanism of fibrogenesis or protection by these HBV 
mutants. 
96 
4.5 Limitation of the Study and Future Work 
4.5.1 Limitation 
The major drawback of the study is the limited sample size. 
Although some results are significant even consider the limited sample 
size and multiple times of statistical calculation, some results may not be 
statistical significant when a large scale of study are performed. It is 
therefore interesting to perform a similar study with a larger sample size to 
examine the findings in this study. 
Multiple comparisons may cause statistical significant results in the 
analysis by chance only, which is indeed a problem in the study. However, 
some of the major findings in this study are quite significant even take the 
times of comparison into consideration. For example, the p-value for the 
protective effect against fibrosis and necro-inflammation at mutant 220IC 
is 0.002 and the time of comparison is far below 25, which highly suggest 
a genuine difference despite the potential error due to multiple 
comparisons. 
Another limitation of this study is the clinical significance of 
subgenotypes in the same city is not tested due to limited sample size. It 
would be interesting to see if the different subgenotypes in the same city 
would show similar results with findings in this study. This comparison 
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requires a larger sample size and therefore a further study might be 
necessary to address the question. 
4.5.2 Future Direction 
With the interesting findings in this study, some further work could 
be done to verify or further investigate the results. A study with a larger 
sample size is necessary to confirm the results, especially the novel 
mutants 2201 associated with liver fibrosis and the disease activity among 
different subgenotypes. The clinical significant of subgenotypes in same 
city / region could also be investigated. 
Some in vitro work could be performed as well. The full-genome 
with mutant 1753 or 2201 could be cloned into hepatocyte cell line and 
study the effect of the mutants on the viral replication and protein 
expression level, cell proliferation and apoptosis rate. The results could 
elucidate the possible mechanism of the effect of mutant on the clinical 





In conclusion, the distribution of HBV genotypes/subgenotypes 
among HBeAg-negative chronic hepatitis B patients is different in the 
three cities of China. The subgenotype Cs is almost exclusively found in 
Southern China (Hong Kong), and Ce is predominant in Beijing and 
Shanghai. As HBV genotype C, particularly subgenotype Cs, is associated 
with more active disease in terms of ALT level and necro-inflammation, 
the difference in genotype distribution may be translated to a difference in 
the pattern of disease activity among HBeAg-negative chronic hepatitis B 
in these areas. 
Although hot-spot mutations at the X gene, basal core promoter 
and precore regions have been suggested to increase the replication ability 
of the vims and/or the risk of hepatocarcinogenesis, we did not show any 
worsening of disease severity among our patients bearing these HBV 
mutants except for V1753T mutant in BCP region. On the other hand, we 
have identified several HBV mutants in the core and Pre-S 1 regions that 
may affect liver fibrosis in HBeAg-negative chronic hepatitis B. The 
mutant 2201 at core gene showed protective effect against liver fibrosis 
and necro-inflammation. The 2201 mutant is exclusively found in 
subgenotype Ce, which would be a possible reason for the mild clinical 
symptom of subgenotype Ce than Cs. The info-gain program has showed 
its power in searching mutants associated with severe liver fibrosis and 
therefore could be used as an important tool in future research. 
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The limitation of sample size is the major drawback of the study 
and future study with larger sample size is necessary. Comparison of 
subgenotypes in same region is useful to validate the results as well. The 
clinical significance of the findings in the study requires further research 
for validation. Some in vitro study could be designed based on the findings 
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